Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline
Ημερομηνία
2022Γλώσσα
en
Λέξη-κλειδί
Επιτομή
[No abstract available]
Collections
Related items
Showing items related by title, author, creator and subject.
-
Mechanisms for cardiorenal protection of sglt-2 inhibitors
(2021)Despite optimal treatment of diabetic kidney disease (DKD) with adequate blood pressure control and agents blocking the renin-angiotensin-system (RAS), the residual cardiorenal risk of these patients remains substantially ... -
SGLT-2 inhibitors in diabetic kidney disease: What lies behind their renoprotective properties?
(2019)Background: Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone-system, the residual risk for nephropathy ... -
Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass
(2022)Introduction Postprandial hypoglycaemia after gastric bypass surgery (also known as postbariatric hypoglycaemia or PBH) is an increasingly encountered clinical problem. PBH is characterised by meal-induced rapid spikes and ...